Nick Tait

Charles River Discovery Research Services UK Ltd. provides drug discovery products and services to various pharmaceutical companies. It focuses on three areas such as kinases, G-protein coupled receptors, and ion channels. The company was founded in 1997 and is headquartered in Kent, the United Kingdom.

Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom.

Part of Charles River Laboratories International, Inc., Cambridge Drug Discovery Holdings Ltd. is a company that researches potential new drugs for the treatment of cancer. The company is based in Cambridge, UK. Cambridge Drug Discovery Holdings was acquired by Charles River Discovery Research Services UK Ltd., part of Charles River Laboratories International, Inc. from November 14, 2005 on June 11, 2001 for $38 million. The British company was founded by Barry Kenny, Jonathan Mark Treherne.

Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom.

Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark.

Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies.

The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012.

Pharmacy2U Ltd. provides online pharmacy services. The firm offers private online doctors, NHS, private prescriptions, over-the-counter medicines, health, beauty products, fine fragrances, and skincare products. The company was founded by Daniel Mark Lee and Steven John Dobson on July 8, 1999 and is headquartered in Leeds, the United Kingdom.

Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002.

Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom.

Part of Aukett Swanke Group Plc, Torpedo Factory Ltd. is a British system integration company that provides professional and managed services for stage, audio visual, and intelligent environments. The company is based in London, UK. Founded in 1960.

Oxitope Pharma BV is a Dutch pharmaceutical start-up founded in 2020 that focuses on discovering and developing medicine for the treatment of inflammatory and cardiovascular diseases caused by oxidative stress. The company is based in Naarden, Netherlands. The Dutch company takes a different approach to the diagnosis and treatment of these diseases by preventing, halting, or reversing acute and chronic diseases driven by oxidized phospholipids. Oxitope Pharma's goal is to enable people to live long and healthy lives. The CEO is John Montana.

Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan.

NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands.